The FDA has revised its COVID-19 vaccination guidelines, now recommending annual shots primarily for seniors and younger individuals with significant health risks. The change follows concerns over the effectiveness of routine vaccinations for low-risk groups, as outlined by FDA officials in a recent publication. There are apprehensions about reduced access to vaccinations in colder months, and experts have raised doubts about the appropriateness of regular doses for low-risk populations. Future recommendations for vaccination will depend on randomized trial data, which may be challenging to obtain.
Although the rapid development of multiple Covid-19 vaccines in 2020 represents a major scientific, medical, and regulatory accomplishment, the benefit of repeat dosing - particularly among low-risk persons... is uncertain.
Due to cost, timeline constraints, and variant evolution, full-scale randomized controlled trials (RCTs) are unlikely for updated seasonal COVID-19 vaccines.
Collection
[
|
...
]